Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_assertion type Assertion NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_head.
- NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_assertion description "[To assess impact on health outcomes and healthcare expenditures of adopting a 21-gene assay for women with early-stage, minimally node-positive, estrogen receptor-positive (N (1-3)/ER) HER2-negative breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_provenance.
- NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_assertion evidence source_evidence_literature NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_provenance.
- NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_assertion SIO_000772 21819166 NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_provenance.
- NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_assertion wasDerivedFrom befree-2016 NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_provenance.
- NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_assertion wasGeneratedBy ECO_0000203 NP914989.RACcUsauxGnCo0OYe7wQhWoq724ld0YiBa_q60o7vVBOc130_provenance.